Head-to-head · Cost-Efficiency Index
Alan Meds vs Hims & Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Alan Meds
Budget-first shoppers who want the lowest sema price plus an oral route nationwide.
Visit Alan MedsHims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersThe verdict
Alan Meds takes it, leading the Cost-Efficiency Index 84 to 83. Rock-bottom $99 semaglutide with an oral option and all-50 access — strong on price, but not LegitScript-verified. Hims & Hers still earns a B — People who want a familiar, app-driven consumer brand and only need semaglutide.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Alan Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Alan Meds | Hims & Hers |
|---|---|---|
| Cost-Efficiency Index | 84/100 | 83/100 |
| Semaglutide / mo | $99/mo | $199/mo |
| Tirzepatide / mo | $145/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,188 | $2,388 |
| Tirzepatide / yr (modeled) | $1,740 | — |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #19 | #22 |
Alan Meds
84/100Where the value is
- $99 semaglutide and $145 tirzepatide — among the cheapest disclosed in the ranking
- Nationwide all-50 access with an oral/sublingual option
- Both molecules published for straightforward cost modeling
The tradeoffs
- Not LegitScript-certified — oversight harder to verify
- Compounded only — no brand-name access
Regulatory note: the FDA issued a warning letter to Alan Health Technologies Inc. dba Alan in February 2026. We still list and link to Alan Meds; you should know the letter is on the public record before you decide.
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.